Condition: Metastatic Prostate Cancer · Intermitent Anti-androgen Therapy · Sponsor: The First Affiliated Hospital with Nanjing Medical University
To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.
This description comes directly from the study's public registry record.
Shangqian Wang · +862568303186 · wsq5501@126.com
Always discuss trial participation with your own doctor first.
| Urology dpt, First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06177015